{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:57:16Z","timestamp":1788361036572,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2301303"],"award-info":[{"award-number":["2021YFC2301303"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2301703"],"award-info":[{"award-number":["2021YFC2301703"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2303700"],"award-info":[{"award-number":["2022YFC2303700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013114","name":"Yunnan Key Research and Development Program","doi-asserted-by":"publisher","award":["202102AA310055"],"award-info":[{"award-number":["202102AA310055"]}],"id":[{"id":"10.13039\/501100013114","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013114","name":"Yunnan Key Research and Development Program","doi-asserted-by":"publisher","award":["202103AC100005"],"award-info":[{"award-number":["202103AC100005"]}],"id":[{"id":"10.13039\/501100013114","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013114","name":"Yunnan Key Research and Development Program","doi-asserted-by":"publisher","award":["202103AQ100001"],"award-info":[{"award-number":["202103AQ100001"]}],"id":[{"id":"10.13039\/501100013114","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971548"],"award-info":[{"award-number":["81971548"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82151218"],"award-info":[{"award-number":["82151218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.apsb.2023.05.030","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T21:20:25Z","timestamp":1685136025000},"page":"3339-3351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration"],"prefix":"10.1016","volume":"13","author":[{"given":"Ying","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Qiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2173-4049","authenticated-orcid":false,"given":"An-Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5469-0324","authenticated-orcid":false,"given":"Yong-Tang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3784-8067","authenticated-orcid":false,"given":"Wei","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2023.05.030_bib1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.05.030_bib2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2023.05.030_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2023.05.030_bib4","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1038\/s41586-020-2202-3","article-title":"Author correction: a new coronavirus associated with human respiratory disease in China","volume":"580","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.05.030_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/22221751.2021.2017757","article-title":"The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron","volume":"11","author":"Zhang","year":"2022","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.apsb.2023.05.030_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/22221751.2021.2022440","article-title":"Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost","volume":"11","author":"Ai","year":"2022","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.apsb.2023.05.030_bib7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/v14030597","article-title":"A five-helix-based SARS-CoV-2 fusion inhibitor targeting heptad repeat 2 domain against SARS-CoV-2 and its variants of concern","volume":"14","author":"Xing","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2023.05.030_bib8","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.05.030_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00635-20","article-title":"Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity","volume":"94","author":"Zhu","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2023.05.030_bib10","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(04)15788-7","article-title":"Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors","volume":"363","author":"Liu","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2023.05.030_bib11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","article-title":"Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein","volume":"17","author":"Xia","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2023.05.030_bib12","doi-asserted-by":"crossref","first-page":"eaav4580","DOI":"10.1126\/sciadv.aav4580","article-title":"A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike","volume":"5","author":"Xia","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2023.05.030_bib13","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41422-022-00746-3","article-title":"A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein","volume":"32","author":"Pang","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2023.05.030_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.24272\/j.issn.2095-8137.2020.329","article-title":"Lower respiratory tract samples are reliable for severe acute respiratory syndrome coronavirus 2 nucleic acid diagnosis and animal model study","volume":"42","author":"Tian","year":"2021","journal-title":"Zool Res"},{"key":"10.1016\/j.apsb.2023.05.030_bib15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2023.05.030_bib16","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.cell.2021.02.033","article-title":"Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera","volume":"184","author":"Supasa","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2023.05.030_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-021-03693-y","article-title":"BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants","volume":"596","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.05.030_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.636532","article-title":"Implications of the novel mutations in the SARS-CoV-2 genome for transmission, disease severity, and the vaccine development","volume":"8","author":"Akkiz","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.apsb.2023.05.030_bib19","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1080\/21645515.2021.1923350","article-title":"Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies","volume":"17","author":"Sharun","year":"2021","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.apsb.2023.05.030_bib20","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41392-020-00402-5","article-title":"RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response","volume":"5","author":"Liu","year":"2020","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2023.05.030_bib21","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1038\/emi.2012.47","article-title":"Emerging virus diseases: can we ever expect the unexpected?.","volume":"1","author":"Howard","year":"2012","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.apsb.2023.05.030_bib22","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMe1212300","article-title":"Emerging human coronaviruses\u2014disease potential and preparedness","volume":"367","author":"Anderson","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2023.05.030_bib23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1126\/science.1176225","article-title":"Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans","volume":"325","author":"Garten","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.05.030_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.881604","article-title":"Preclinical assessment of IgY antibodies against recombinant SARS-CoV-2 RBD protein for prophylaxis and post-infection treatment of COVID-19","volume":"13","author":"Agurto-Arteaga","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2023.05.030_bib25","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.apsb.2021.07.026","article-title":"A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases","volume":"12","author":"Zhou","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.05.030_bib26","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41422-022-00617-x","article-title":"Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant","volume":"32","author":"Xia","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2023.05.030_bib27","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/ncomms4067","article-title":"Structure-based discovery of middle east respiratory syndrome coronavirus fusion inhibitor","volume":"5","author":"Lu","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.05.030_bib28","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/infdis\/jiv325","article-title":"Protective effect of intranasal regimens containing peptidic middle east respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection","volume":"212","author":"Channappanavar","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.apsb.2023.05.030_bib29","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41392-021-00712-2","article-title":"Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation","volume":"6","author":"Xia","year":"2021","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2023.05.030_bib30","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1016\/j.apsb.2021.05.007","article-title":"SARS-CoV-2 cell entry and targeted antiviral development","volume":"11","author":"Chen","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.05.030_bib31","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1126\/science.abj3321","article-title":"Broad betacoronavirus neutralization by a stem helix-specific human antibody","volume":"373","author":"Pinto","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.05.030_bib32","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1080\/22221751.2022.2095308","article-title":"An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological- and endosomal-pH to inhibit virus entry","volume":"11","author":"Lin","year":"2022","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.apsb.2023.05.030_bib33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/v15030687","article-title":"Intranasal boosting with spike Fc-RBD of wild-type SARS-CoV-2 induces neutralizing antibodies against Omicron subvariants and reduces viral load in the nasal turbinate of mice","volume":"15","author":"Cai","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2023.05.030_bib34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41392-020-00434-x","article-title":"Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2","volume":"5","author":"Lei","year":"2020","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2023.05.030_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28641","article-title":"SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors","volume":"95","author":"Xia","year":"2023","journal-title":"J Med Virol"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523001922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523001922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:59:08Z","timestamp":1761929948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383523001922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2211383523001922"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2023.05.030","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2023.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}